<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Cytel</id>
	<title>Cytel - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Cytel"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Cytel&amp;action=history"/>
	<updated>2026-04-25T01:38:54Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Cytel&amp;diff=4967305&amp;oldid=prev</id>
		<title>Prab at 19:03, 8 September 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Cytel&amp;diff=4967305&amp;oldid=prev"/>
		<updated>2023-09-08T19:03:34Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;Cytel, Inc.&amp;#039;&amp;#039;&amp;#039; is a pioneering clinical trial design service provider headquartered in [[Cambridge, Massachusetts]], USA. The company offers specialized statistical applications and services, catering primarily to the biotech and pharmaceutical research sectors.&lt;br /&gt;
&lt;br /&gt;
=== Overview ===&lt;br /&gt;
&lt;br /&gt;
Established in Cambridge, the hub of biotechnology and pharmaceutical innovation, Cytel plays a pivotal role in enhancing the efficiency and efficacy of clinical trials through its avant-garde statistical methodologies.&lt;br /&gt;
&lt;br /&gt;
=== Specialization in Adaptive Trials ===&lt;br /&gt;
&lt;br /&gt;
Cytel has carved a niche in the realm of &amp;#039;&amp;#039;&amp;#039;adaptive trials&amp;#039;&amp;#039;&amp;#039;, an innovative type of randomized clinical trial. This approach permits the incorporation of modifications to ongoing trials, while safeguarding the trial&amp;#039;s statistical validity and overall integrity.&lt;br /&gt;
&lt;br /&gt;
These adaptive trial designs, grounded on either [[frequentist]] or [[Bayesian statistics]], facilitate more flexible decision-making processes during a trial, allowing researchers to adjust based on accumulating data. Such a dynamic approach ensures that patient interests are preserved, the trial remains relevant, and resources are optimally utilized.&lt;br /&gt;
&lt;br /&gt;
Increasingly, major regulatory bodies, such as the:&lt;br /&gt;
* [[United States Food and Drug Administration (FDA)]]&lt;br /&gt;
* [[European Medicines Agency (EMA)]]&lt;br /&gt;
* [[Medicines and Healthcare products Regulatory Agency (MHRA)]]&lt;br /&gt;
&lt;br /&gt;
have begun recognizing and endorsing adaptive trial designs for both early and later stage clinical research.&lt;br /&gt;
&lt;br /&gt;
=== Clientele and Software Adoption ===&lt;br /&gt;
&lt;br /&gt;
By January 2014, Cytel affirmed that its software tools, integral for trial design, simulation, and analysis, were being actively utilized by all top 25 biopharmaceutical enterprises. Such widespread adoption underscores Cytel&amp;#039;s significant contributions to the domain of clinical trial research and its pivotal role in fostering innovative methodologies.&lt;br /&gt;
&lt;br /&gt;
== See Also ==&lt;br /&gt;
* [[Clinical trial design]]&lt;br /&gt;
* [[Biostatistics]]&lt;br /&gt;
* [[Bayesian statistics]]&lt;br /&gt;
* [[Pharmaceutical industry]]&lt;br /&gt;
{{stub}}&lt;br /&gt;
{{Contract research organization|state=collapsed}}&lt;br /&gt;
[[Category:Biotechnology companies of the United States]]&lt;br /&gt;
[[Category:Companies based in Massachusetts]]&lt;br /&gt;
[[Category:Contract research organizations]]&lt;br /&gt;
[[Category:Companies formerly listed on the Nasdaq]]&lt;br /&gt;
[[Category:Drug discovery companies]]&lt;br /&gt;
[[Category:Statistical service organizations]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>